医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Dr. Reddy’s Laboratories Announces Senior Leadership Changes

2018年03月29日 PM02:45
このエントリーをはてなブックマークに追加


 

HYDERABAD, India

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced a change in the makeup of its senior leadership team.

Following a 15-year career with the company, Mr. Abhijit Mukherjee, Chief Operating Officer, will retire on March 31, 2018.

Mr. Mukherjee will be succeeded by Mr. Erez Israeli, former President & CEO of Enzymotec. Mr. Israeli will join Dr. Reddy’s on April 2, 2018, as Chief Operating Officer and Global Head of Generics & PSAI, based out of Hyderabad. He will report to Dr. Reddy’s Co-Chairman & CEO, G.V. Prasad.

In a career spanning over 25 years, Israeli has held leadership positions that have contributed significantly to the performance of companies he worked for. Prior to Enzymotec, he completed 23 years with Teva Pharmaceuticals Limited, where he held several positions of responsibility including Vice President Marketing & Sales for North America, Vice President Asia Operations, President Teva API, Group Executive Vice President, Head of Global Quality, and President & CEO Growth Markets.

Speaking about the transition, G.V. Prasad said, “I would like to thank Abhijit for his valuable contribution to our company’s growth journey over the past fifteen years. I extend a warm welcome to Erez Israeli. Erez is an accomplished leader with a proven track record of achievement. His knowledge and experience from leading pharmaceutical businesses of scale will be valuable for our future growth.”

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses – Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words “may”, “will”, “should”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential”, or “continue” and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180328006275/en/

CONTACT

INVESTOR RELATIONS
SAUNAK SAVLA
+91-40-49002135
saunaks@drreddys.com
or
MEDIA
RELATIONS

CALVIN PRINTER
+91-40-49002121
calvinprinter@drreddys.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Scientist.comがインク誌から「米国内で最も急成長中の非公開企業」のトップ10に指名される
  • Urban Drinking Water Challenge 2018 Announces Winners from USA, India and Bangladesh
  • CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) In China
  • AVEO Announces Acceptance of CANbridge Investigational New Drug Application for CAN017 (AV-203) Trial in Esophageal Squamous Cell Cancer (ESCC) in China
  • STAAR Surgical and Shinjuku LASIK Clinic in Japan Announce Strategic Cooperation Agreement